Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Merck (MSD) declined to exercise its option on Evaxion's protein-based gonorrhea vaccine candidate EVX-B2, leaving global rights with Evaxion which will seek another licensing partner; Evaxion says the decision does not affect its cash runway, which it expects to extend to the second half of 2027. Separately, Evaxion out-licensed EVX-B3 to Merck in September 2024 for a $7.5 million upfront payment and potential development/regulatory/sales milestones of up to $592 million plus royalties, while Evaxion continues development of an mRNA version of EVX-B2 with Afrigen. Market reaction was negative for EVAX (share price down ~14.61% to $4.91), and competitive/regulatory context includes the FDA approval of GSK's gepotidacin for uncomplicated urogenital gonorrhea.

Analysis

Market structure: Immediate winners are competitors with late-stage therapeutics (GSK; NYSE:GSK) — an FDA-approved oral for uncomplicated gonorrhoea reduces near-term demand for a vaccine and redistributes near-term commercial value into therapeutics. Losers are Evaxion (NASDAQ:EVAX) equity holders (stock down ~15% on the news) and biotech peers that rely on Big Pharma take-licenses; Merck (MRK) is neutral-to-slight-negative but has limited balance-sheet impact. The vaccine market remains large (80M annual infections), so long-term demand for a prophylactic (pricing power, public-health procurement) persists even if near-term revenue shifts to drugs.

Risk assessment: Tail risks include EVAX preclinical/IND failure, inability to find a partner leading to dilutive financing, or regulatory setbacks for mRNA/protein platforms — each could cut equity value >50%. Time horizons: days — repricing/liquidity shock already happened; weeks–months — partner talks, Afrigen mRNA progress, and potential equity raises; quarters–years — clinical development and commercialization (3–7+ years). Hidden dependencies: EVX-B3 progress with Merck and Afrigen tech-transfer timelines strongly determine EVAX bargaining power; absence of partner within 6–12 months materially increases dilution risk.

Trade implications: Tactical plays favor small, event-driven exposure to EVAX with hedges: asymmetric option exposure (buy calls) or a paired long EVAX/short broad biotech (e.g., IBB) to isolate idiosyncratic upside. Consider modest long exposure to GSK (1–2% of portfolio) to capture incremental sales from gepotidacin adoption over 6–12 months; sector vols likely elevated — implied vol spikes favor buying premium for EVAX rather than writing it. Key catalysts to trade around: partner announcement (target window 3–12 months), Afrigen mRNA IND or Merck EVX-B3 updates (12–36 months).

Contrarian angle: The market may be over-discounting EVAX: management explicitly says the decision doesn't change cash runway to H2 2027, so downside is limited absent acute negative news; a re-partnering deal within 12 months could re-rate the stock 2–5x as seen in prior small-cap biotech re-licenses. Conversely, if no partner and runway assumptions change, downside >50% is plausible. Action should be event-driven and size-constrained given binary outcomes.

Key Decisions for Investors

• Establish a tactical 2% long position in EVAX (NASDAQ:EVAX) as an event-driven spec: size 2% of fund NAV, set a hard stop-loss at 30% below entry (~$3.45 if entry at $4.92) and a take-profit zone of 2–3x within 12–24 months contingent on a licensing announcement or positive Afrigen mRNA IND filing.
• Implement an options asymmetric play instead of a larger equity stake: buy EVAX 6-month ATM calls (expiry Jun 2026) sized to 0.75% premium exposure; if liquidity allows prefer Jun 2026 $5 calls to capture re-rating on partner news while limiting downside to premium paid.
• Pair trade to neutralize sector beta: long EVAX 2% / short IBB (iShares Nasdaq Biotechnology ETF) 1% notional to isolate idiosyncratic upside while hedging broad biotech volatility; rebalance if IBB outperforms by >8% in 60 days.
• Allocate 1–2% to GSK (NYSE:GSK) long exposure to capture uptake of gepotidacin over 6–12 months; target +10–20% return, stop-loss -8% from entry. Exit or trim if real-world evidence or prescribing uptake in the next 3–6 months disappoints.
• Exit criteria / monitoring: if Evaxion fails to announce a strategic partner or materially revises cash runway prior to H2 2027 (within 12 months), reduce EVAX exposure to zero; conversely, if an upfront licensing payment >=$7.5M or binding deal announced, increase EVAX to 3–4% and reassess clinical milestone timelines.